| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 29 | 2024 | 1794 | 2.470 |
Why?
|
| Hepatitis C, Chronic | 12 | 2018 | 367 | 1.920 |
Why?
|
| Liver Cirrhosis | 15 | 2018 | 900 | 1.640 |
Why?
|
| Hepatitis C | 8 | 2018 | 390 | 1.180 |
Why?
|
| Liver Neoplasms | 10 | 2024 | 1386 | 1.170 |
Why?
|
| Carcinoma, Hepatocellular | 8 | 2024 | 998 | 1.030 |
Why?
|
| HIV Infections | 15 | 2025 | 2037 | 1.030 |
Why?
|
| Head and Neck Neoplasms | 4 | 2025 | 631 | 0.900 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2023 | 268 | 0.890 |
Why?
|
| Sarcoma, Kaposi | 3 | 2022 | 130 | 0.850 |
Why?
|
| Papillomavirus Infections | 3 | 2023 | 389 | 0.820 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2020 | 667 | 0.820 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2023 | 758 | 0.750 |
Why?
|
| Colon | 6 | 2025 | 360 | 0.730 |
Why?
|
| Gastrointestinal Microbiome | 8 | 2025 | 833 | 0.730 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2021 | 36 | 0.710 |
Why?
|
| Middle Aged | 53 | 2025 | 28839 | 0.700 |
Why?
|
| Hepacivirus | 5 | 2017 | 273 | 0.690 |
Why?
|
| Liver Diseases | 4 | 2015 | 381 | 0.680 |
Why?
|
| Algorithms | 5 | 2019 | 1685 | 0.680 |
Why?
|
| Receptor for Advanced Glycation End Products | 2 | 2018 | 32 | 0.670 |
Why?
|
| Polymorphism, Genetic | 3 | 2015 | 794 | 0.630 |
Why?
|
| alpha-Fetoproteins | 3 | 2018 | 139 | 0.610 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2019 | 132 | 0.580 |
Why?
|
| Irritable Bowel Syndrome | 4 | 2024 | 217 | 0.570 |
Why?
|
| Diet | 4 | 2025 | 1119 | 0.570 |
Why?
|
| United States Department of Veterans Affairs | 6 | 2024 | 713 | 0.570 |
Why?
|
| Intestinal Mucosa | 6 | 2025 | 764 | 0.550 |
Why?
|
| Parkinson Disease | 2 | 2020 | 725 | 0.540 |
Why?
|
| Adipokines | 1 | 2018 | 121 | 0.530 |
Why?
|
| Speech-Language Pathology | 1 | 2017 | 13 | 0.520 |
Why?
|
| Speech Therapy | 1 | 2017 | 15 | 0.520 |
Why?
|
| Juvenile Delinquency | 1 | 2017 | 25 | 0.510 |
Why?
|
| Humans | 87 | 2025 | 131504 | 0.480 |
Why?
|
| Aged | 31 | 2025 | 21238 | 0.480 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 314 | 0.480 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1617 | 0.460 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 731 | 0.450 |
Why?
|
| Male | 50 | 2025 | 65158 | 0.440 |
Why?
|
| United States | 26 | 2024 | 11794 | 0.440 |
Why?
|
| Risk | 5 | 2020 | 739 | 0.430 |
Why?
|
| Esophageal Neoplasms | 5 | 2020 | 392 | 0.430 |
Why?
|
| Persian Gulf Syndrome | 2 | 2024 | 16 | 0.420 |
Why?
|
| Risk Factors | 21 | 2024 | 10952 | 0.420 |
Why?
|
| Incidence | 12 | 2024 | 3344 | 0.410 |
Why?
|
| Fatty Liver | 2 | 2012 | 215 | 0.400 |
Why?
|
| Case-Control Studies | 9 | 2024 | 3452 | 0.390 |
Why?
|
| Body Fat Distribution | 1 | 2012 | 32 | 0.380 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 297 | 0.380 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 714 | 0.370 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 206 | 0.370 |
Why?
|
| Finasteride | 1 | 2012 | 16 | 0.370 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2012 | 14 | 0.370 |
Why?
|
| Bibliometrics | 1 | 2012 | 39 | 0.370 |
Why?
|
| Cross-Sectional Studies | 14 | 2025 | 3834 | 0.370 |
Why?
|
| Review Literature as Topic | 1 | 2012 | 52 | 0.370 |
Why?
|
| Peer Review, Research | 1 | 2012 | 45 | 0.370 |
Why?
|
| Adult | 27 | 2025 | 31666 | 0.370 |
Why?
|
| Narcotics | 1 | 2012 | 59 | 0.370 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 85 | 0.360 |
Why?
|
| Diabetes Mellitus | 4 | 2023 | 886 | 0.360 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 169 | 0.360 |
Why?
|
| Methadone | 1 | 2012 | 126 | 0.360 |
Why?
|
| Electronic Health Records | 2 | 2019 | 809 | 0.350 |
Why?
|
| Female | 45 | 2025 | 71087 | 0.340 |
Why?
|
| Vitamin D | 1 | 2013 | 194 | 0.340 |
Why?
|
| Adiposity | 1 | 2012 | 207 | 0.340 |
Why?
|
| Bacteria | 5 | 2025 | 532 | 0.330 |
Why?
|
| Disease Progression | 3 | 2022 | 2205 | 0.330 |
Why?
|
| Postmenopause | 5 | 2018 | 149 | 0.330 |
Why?
|
| Barrett Esophagus | 4 | 2020 | 356 | 0.320 |
Why?
|
| Spouse Abuse | 1 | 2009 | 15 | 0.310 |
Why?
|
| Sex Offenses | 1 | 2010 | 52 | 0.310 |
Why?
|
| Gastroenterology | 1 | 2012 | 220 | 0.310 |
Why?
|
| Caffeine | 2 | 2023 | 66 | 0.300 |
Why?
|
| Feeding Behavior | 2 | 2015 | 724 | 0.300 |
Why?
|
| Inflammation | 4 | 2020 | 1490 | 0.290 |
Why?
|
| Sex Factors | 5 | 2019 | 1345 | 0.280 |
Why?
|
| Aggression | 1 | 2009 | 221 | 0.270 |
Why?
|
| Anti-HIV Agents | 2 | 2022 | 359 | 0.270 |
Why?
|
| Motor Activity | 1 | 2010 | 508 | 0.270 |
Why?
|
| Prevalence | 8 | 2024 | 2692 | 0.270 |
Why?
|
| Obesity | 4 | 2022 | 2379 | 0.260 |
Why?
|
| Prospective Studies | 12 | 2021 | 6485 | 0.260 |
Why?
|
| Glutathione Transferase | 1 | 2007 | 145 | 0.260 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 395 | 0.250 |
Why?
|
| RNA, Ribosomal, 16S | 6 | 2025 | 386 | 0.240 |
Why?
|
| Coffee | 3 | 2023 | 30 | 0.240 |
Why?
|
| Testosterone | 1 | 2011 | 603 | 0.240 |
Why?
|
| Risk Assessment | 8 | 2024 | 3693 | 0.240 |
Why?
|
| Surveys and Questionnaires | 8 | 2024 | 4037 | 0.240 |
Why?
|
| Substance-Related Disorders | 2 | 2009 | 493 | 0.230 |
Why?
|
| Logistic Models | 4 | 2024 | 1831 | 0.230 |
Why?
|
| Age Factors | 5 | 2019 | 2870 | 0.230 |
Why?
|
| Adenocarcinoma | 4 | 2020 | 999 | 0.230 |
Why?
|
| Dairy Products | 1 | 2025 | 43 | 0.220 |
Why?
|
| Retrospective Studies | 14 | 2025 | 17648 | 0.220 |
Why?
|
| Penile Neoplasms | 1 | 2024 | 37 | 0.210 |
Why?
|
| Cohort Studies | 10 | 2025 | 5120 | 0.210 |
Why?
|
| Interleukins | 2 | 2015 | 121 | 0.200 |
Why?
|
| Immunogenetics | 1 | 2023 | 10 | 0.200 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2023 | 25 | 0.200 |
Why?
|
| Alcohol Drinking | 3 | 2020 | 348 | 0.190 |
Why?
|
| HIV | 2 | 2021 | 179 | 0.190 |
Why?
|
| Trans Fatty Acids | 1 | 2022 | 13 | 0.190 |
Why?
|
| Antiviral Agents | 3 | 2017 | 812 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2024 | 3411 | 0.180 |
Why?
|
| Sleep | 2 | 2017 | 373 | 0.180 |
Why?
|
| Hyperlipidemias | 1 | 2023 | 188 | 0.180 |
Why?
|
| Odds Ratio | 3 | 2010 | 1235 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 6916 | 0.180 |
Why?
|
| Calcium-Binding Proteins | 1 | 2023 | 328 | 0.180 |
Why?
|
| Comorbidity | 4 | 2020 | 1590 | 0.170 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 222 | 0.170 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2018 | 403 | 0.170 |
Why?
|
| Anus Neoplasms | 1 | 2021 | 43 | 0.170 |
Why?
|
| Registries | 2 | 2019 | 1599 | 0.170 |
Why?
|
| Tooth Loss | 1 | 2020 | 4 | 0.170 |
Why?
|
| Principal Component Analysis | 2 | 2018 | 153 | 0.170 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 95 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 46 | 0.170 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 120 | 0.160 |
Why?
|
| Patient Readmission | 2 | 2015 | 423 | 0.160 |
Why?
|
| Neoplasms | 4 | 2021 | 2969 | 0.160 |
Why?
|
| Periodontal Diseases | 1 | 2020 | 33 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2023 | 489 | 0.160 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 2 | 2017 | 24 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2019 | 2143 | 0.150 |
Why?
|
| Geography | 1 | 2019 | 119 | 0.150 |
Why?
|
| Burkitt Lymphoma | 1 | 2020 | 134 | 0.140 |
Why?
|
| Databases, Factual | 3 | 2020 | 1223 | 0.140 |
Why?
|
| HIV Protease Inhibitors | 1 | 2018 | 44 | 0.140 |
Why?
|
| Health Services Administration | 1 | 2018 | 9 | 0.140 |
Why?
|
| Osteoarthritis, Knee | 1 | 2022 | 280 | 0.140 |
Why?
|
| Plasminogen Inactivators | 1 | 2018 | 5 | 0.140 |
Why?
|
| Young Adult | 4 | 2019 | 10092 | 0.140 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 156 | 0.140 |
Why?
|
| Colorectal Neoplasms | 2 | 2016 | 638 | 0.140 |
Why?
|
| Gout | 1 | 2021 | 173 | 0.140 |
Why?
|
| Diet, Fat-Restricted | 1 | 2018 | 37 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 2985 | 0.140 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 114 | 0.130 |
Why?
|
| Adiponectin | 1 | 2018 | 124 | 0.130 |
Why?
|
| Mexican Americans | 1 | 2018 | 166 | 0.130 |
Why?
|
| Prisons | 1 | 2017 | 16 | 0.130 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2017 | 66 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 131 | 0.130 |
Why?
|
| Criminals | 1 | 2017 | 20 | 0.130 |
Why?
|
| Hypertension | 2 | 2023 | 1357 | 0.130 |
Why?
|
| Receptors, Ghrelin | 1 | 2016 | 29 | 0.120 |
Why?
|
| Leptin | 1 | 2018 | 218 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 1839 | 0.120 |
Why?
|
| Ghrelin | 1 | 2016 | 57 | 0.120 |
Why?
|
| Severity of Illness Index | 6 | 2018 | 3090 | 0.120 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 409 | 0.120 |
Why?
|
| Nutritional Sciences | 1 | 2016 | 66 | 0.120 |
Why?
|
| Focus Groups | 1 | 2017 | 228 | 0.120 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2015 | 5 | 0.120 |
Why?
|
| Language Development Disorders | 1 | 2017 | 178 | 0.120 |
Why?
|
| Alcohol Abstinence | 1 | 2015 | 15 | 0.120 |
Why?
|
| ROC Curve | 1 | 2017 | 615 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 1404 | 0.120 |
Why?
|
| Arthroplasty, Replacement | 1 | 2015 | 27 | 0.110 |
Why?
|
| Microbiota | 1 | 2020 | 441 | 0.110 |
Why?
|
| Bias | 2 | 2013 | 144 | 0.110 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2020 | 228 | 0.110 |
Why?
|
| Mortality | 1 | 2016 | 261 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 1956 | 0.110 |
Why?
|
| Health Education | 1 | 2016 | 229 | 0.110 |
Why?
|
| Elective Surgical Procedures | 1 | 2015 | 157 | 0.110 |
Why?
|
| Hospitals, Veterans | 2 | 2018 | 346 | 0.110 |
Why?
|
| Gulf War | 2 | 2024 | 10 | 0.110 |
Why?
|
| Endosonography | 1 | 2014 | 79 | 0.110 |
Why?
|
| Disease Management | 1 | 2018 | 563 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2016 | 1409 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 1405 | 0.100 |
Why?
|
| Colorectal Surgery | 1 | 2013 | 11 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2015 | 199 | 0.100 |
Why?
|
| Diet Records | 1 | 2013 | 70 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2024 | 2862 | 0.100 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 578 | 0.100 |
Why?
|
| Hepatitis | 1 | 2013 | 57 | 0.100 |
Why?
|
| Alcoholism | 1 | 2015 | 246 | 0.100 |
Why?
|
| Fructose | 1 | 2013 | 61 | 0.100 |
Why?
|
| Optical Imaging | 1 | 2013 | 76 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 2297 | 0.100 |
Why?
|
| Behavior Therapy | 1 | 2015 | 270 | 0.100 |
Why?
|
| Dietary Carbohydrates | 1 | 2013 | 108 | 0.100 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2012 | 50 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2018 | 785 | 0.090 |
Why?
|
| Mass Screening | 1 | 2018 | 825 | 0.090 |
Why?
|
| Data Collection | 2 | 2010 | 371 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2018 | 1682 | 0.090 |
Why?
|
| Neurofibrillary Tangles | 1 | 1991 | 29 | 0.090 |
Why?
|
| Endoscopy | 1 | 2013 | 282 | 0.090 |
Why?
|
| Time Factors | 4 | 2017 | 6273 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2081 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 506 | 0.080 |
Why?
|
| Papillomaviridae | 2 | 2022 | 179 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2013 | 492 | 0.080 |
Why?
|
| Hepatitis B | 2 | 2010 | 174 | 0.080 |
Why?
|
| Quality of Life | 3 | 2009 | 2107 | 0.080 |
Why?
|
| Endemic Diseases | 1 | 2010 | 61 | 0.080 |
Why?
|
| Vietnam Conflict | 1 | 2009 | 9 | 0.080 |
Why?
|
| Viral Load | 1 | 2011 | 406 | 0.080 |
Why?
|
| Vietnam | 1 | 2009 | 66 | 0.080 |
Why?
|
| Afghan Campaign 2001- | 1 | 2009 | 118 | 0.080 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2009 | 126 | 0.080 |
Why?
|
| Biomarkers | 3 | 2018 | 3403 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2007 | 215 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 1254 | 0.070 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2007 | 25 | 0.070 |
Why?
|
| Dyspepsia | 1 | 2008 | 108 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2007 | 272 | 0.070 |
Why?
|
| Feces | 2 | 2021 | 725 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2007 | 216 | 0.070 |
Why?
|
| Military Personnel | 1 | 2009 | 209 | 0.070 |
Why?
|
| Unsafe Sex | 1 | 2007 | 23 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2025 | 1322 | 0.060 |
Why?
|
| Central Nervous System Stimulants | 2 | 2007 | 128 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2010 | 467 | 0.060 |
Why?
|
| Medical Records | 1 | 2007 | 180 | 0.060 |
Why?
|
| Methamphetamine | 1 | 2007 | 50 | 0.060 |
Why?
|
| Adolescent | 3 | 2017 | 20917 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2007 | 197 | 0.060 |
Why?
|
| Genotype | 2 | 2013 | 2655 | 0.060 |
Why?
|
| Prognosis | 1 | 2015 | 4951 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 569 | 0.060 |
Why?
|
| Coinfection | 2 | 2017 | 192 | 0.060 |
Why?
|
| Texas | 2 | 2012 | 3614 | 0.060 |
Why?
|
| Cheese | 1 | 2025 | 8 | 0.060 |
Why?
|
| Yogurt | 1 | 2025 | 13 | 0.060 |
Why?
|
| Adolescent Behavior | 1 | 2007 | 171 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 310 | 0.060 |
Why?
|
| Treatment Outcome | 6 | 2021 | 12936 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 340 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2007 | 844 | 0.050 |
Why?
|
| Needlestick Injuries | 1 | 2003 | 6 | 0.050 |
Why?
|
| Protective Devices | 1 | 2003 | 8 | 0.050 |
Why?
|
| Aging | 1 | 1991 | 1264 | 0.050 |
Why?
|
| Research Design | 1 | 2008 | 722 | 0.050 |
Why?
|
| Survival Rate | 2 | 2020 | 2149 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 1991 | 876 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2008 | 562 | 0.050 |
Why?
|
| North America | 1 | 2024 | 256 | 0.050 |
Why?
|
| Interferons | 2 | 2015 | 136 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2019 | 773 | 0.050 |
Why?
|
| Cardiomyopathies | 1 | 2008 | 514 | 0.050 |
Why?
|
| Smoking | 2 | 2019 | 926 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 2003 | 78 | 0.050 |
Why?
|
| Circadian Rhythm | 2 | 2017 | 315 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2022 | 33 | 0.050 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2022 | 50 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2022 | 89 | 0.050 |
Why?
|
| Nurses | 1 | 2003 | 79 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2024 | 359 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2021 | 15 | 0.040 |
Why?
|
| Catheterization, Peripheral | 1 | 2003 | 129 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 743 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2013 | 3113 | 0.040 |
Why?
|
| Sample Size | 2 | 2013 | 86 | 0.040 |
Why?
|
| Knee Joint | 1 | 2022 | 173 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2022 | 276 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2020 | 33 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2022 | 293 | 0.040 |
Why?
|
| Oral Health | 1 | 2020 | 28 | 0.040 |
Why?
|
| Intraocular Pressure | 1 | 2021 | 133 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2022 | 263 | 0.040 |
Why?
|
| Radiography | 1 | 2022 | 760 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2022 | 362 | 0.040 |
Why?
|
| Weight Gain | 1 | 2022 | 383 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 210 | 0.040 |
Why?
|
| Heart Failure | 2 | 2016 | 2306 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 23 | 0.040 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2018 | 40 | 0.040 |
Why?
|
| Platelet Count | 1 | 2018 | 140 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 97 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 3911 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 192 | 0.040 |
Why?
|
| Body Weight | 1 | 2022 | 986 | 0.030 |
Why?
|
| Edible Grain | 1 | 2018 | 43 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 61 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 492 | 0.030 |
Why?
|
| Protective Factors | 1 | 2018 | 93 | 0.030 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 87 | 0.030 |
Why?
|
| Life Style | 1 | 2020 | 444 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 144 | 0.030 |
Why?
|
| Animals | 6 | 2025 | 34341 | 0.030 |
Why?
|
| Sleep Apnea Syndromes | 1 | 1998 | 94 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 1249 | 0.030 |
Why?
|
| Phenotype | 2 | 2022 | 4517 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 306 | 0.030 |
Why?
|
| Women's Health | 1 | 2017 | 143 | 0.030 |
Why?
|
| Child | 1 | 2017 | 26239 | 0.030 |
Why?
|
| Fruit | 1 | 2018 | 234 | 0.030 |
Why?
|
| Schizophrenia | 1 | 1979 | 331 | 0.030 |
Why?
|
| Vegetables | 1 | 2018 | 271 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 97 | 0.030 |
Why?
|
| Paris | 1 | 2015 | 11 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 558 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 1979 | 379 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 418 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 1745 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2016 | 302 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 387 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 872 | 0.030 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 189 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 510 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2018 | 972 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 5277 | 0.030 |
Why?
|
| Contraindications | 1 | 2013 | 77 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2013 | 83 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 750 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 611 | 0.020 |
Why?
|
| Surgery, Plastic | 1 | 1993 | 114 | 0.020 |
Why?
|
| Amyloid | 1 | 1991 | 76 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2116 | 0.020 |
Why?
|
| Asia, Southeastern | 1 | 2010 | 22 | 0.020 |
Why?
|
| Ambulatory Care | 2 | 2007 | 406 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2010 | 120 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 214 | 0.020 |
Why?
|
| Antidepressive Agents | 2 | 1979 | 332 | 0.020 |
Why?
|
| Helicobacter pylori | 1 | 2019 | 1358 | 0.020 |
Why?
|
| Length of Stay | 1 | 2015 | 1393 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 651 | 0.020 |
Why?
|
| Patient Selection | 1 | 2013 | 723 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 865 | 0.020 |
Why?
|
| Overweight | 1 | 2012 | 377 | 0.020 |
Why?
|
| Brain Mapping | 1 | 1991 | 389 | 0.020 |
Why?
|
| Autonomic Agents | 1 | 2008 | 3 | 0.020 |
Why?
|
| Selenoproteins | 1 | 2008 | 12 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 691 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2008 | 102 | 0.020 |
Why?
|
| Ubiquinone | 1 | 2008 | 27 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2008 | 101 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1991 | 1610 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2012 | 678 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 142 | 0.020 |
Why?
|
| Ventricular Remodeling | 1 | 2008 | 155 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2008 | 183 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 235 | 0.020 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2008 | 226 | 0.020 |
Why?
|
| Receptors, Adrenergic | 1 | 1976 | 18 | 0.020 |
Why?
|
| Streptomyces griseus | 1 | 1975 | 1 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2007 | 164 | 0.010 |
Why?
|
| Hexosaminidases | 1 | 1975 | 7 | 0.010 |
Why?
|
| Hippocampus | 1 | 1991 | 805 | 0.010 |
Why?
|
| Acetylglucosaminidase | 1 | 1975 | 12 | 0.010 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 1975 | 19 | 0.010 |
Why?
|
| Digitoxin | 1 | 1975 | 12 | 0.010 |
Why?
|
| Biogenic Amines | 1 | 1975 | 17 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 303 | 0.010 |
Why?
|
| Antioxidants | 1 | 2008 | 336 | 0.010 |
Why?
|
| Global Health | 1 | 2010 | 632 | 0.010 |
Why?
|
| Microsomes, Liver | 1 | 1975 | 96 | 0.010 |
Why?
|
| Stroke | 1 | 2013 | 1049 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 469 | 0.010 |
Why?
|
| Dopamine | 1 | 1975 | 256 | 0.010 |
Why?
|
| Pedigree | 1 | 2008 | 1710 | 0.010 |
Why?
|
| Time | 1 | 2003 | 96 | 0.010 |
Why?
|
| Inservice Training | 1 | 2003 | 55 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2007 | 506 | 0.010 |
Why?
|
| Hospitals, Urban | 1 | 2003 | 99 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 1975 | 389 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2003 | 109 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1993 | 1213 | 0.010 |
Why?
|
| Myocardium | 1 | 2008 | 874 | 0.010 |
Why?
|
| Organizational Culture | 1 | 2003 | 94 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 1139 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 1347 | 0.010 |
Why?
|
| In Vitro Techniques | 3 | 1975 | 824 | 0.010 |
Why?
|
| Convulsive Therapy | 1 | 1979 | 1 | 0.010 |
Why?
|
| Social Adjustment | 1 | 1979 | 79 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 1979 | 83 | 0.010 |
Why?
|
| Electroconvulsive Therapy | 1 | 1979 | 85 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 1998 | 124 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1998 | 300 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 902 | 0.010 |
Why?
|
| Syndrome | 1 | 1979 | 1166 | 0.010 |
Why?
|
| NADP | 2 | 1975 | 54 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 1979 | 364 | 0.010 |
Why?
|
| Structure-Activity Relationship | 2 | 1976 | 579 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1998 | 1450 | 0.010 |
Why?
|
| Kinetics | 2 | 1975 | 1101 | 0.010 |
Why?
|
| Rats | 2 | 1975 | 3454 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1976 | 152 | 0.000 |
Why?
|
| Fucose | 1 | 1975 | 18 | 0.000 |
Why?
|
| Depression, Chemical | 1 | 1975 | 35 | 0.000 |
Why?
|
| Digitoxigenin | 1 | 1975 | 10 | 0.000 |
Why?
|
| Homovanillic Acid | 1 | 1975 | 30 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1975 | 43 | 0.000 |
Why?
|
| Propranolol | 1 | 1976 | 111 | 0.000 |
Why?
|
| Hydroxylation | 1 | 1975 | 51 | 0.000 |
Why?
|
| Oligosaccharides | 1 | 1975 | 74 | 0.000 |
Why?
|
| Epinephrine | 1 | 1976 | 150 | 0.000 |
Why?
|
| Sheep | 1 | 1975 | 224 | 0.000 |
Why?
|
| Species Specificity | 1 | 1975 | 519 | 0.000 |
Why?
|
| Binding Sites | 1 | 1976 | 1202 | 0.000 |
Why?
|
| Brain | 2 | 1975 | 3237 | 0.000 |
Why?
|
| Pyrimidines | 1 | 1975 | 443 | 0.000 |
Why?
|
| Protein Binding | 1 | 1976 | 1710 | 0.000 |
Why?
|